Discovery of FHD-286, a First-in-Class, Orally Bioavailable, Allosteric Dual Inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase Activity for the Treatment of SWItch/Sucrose Non-Fermentable (SWI/SNF) Dependent Cancers.
Vaswani RG, Huang DS, Anthony N, Xu L, Centore R, Schiller S, Li Z, Fan H, Setser J, Zawadzke LE, Davenport Y, Chen X, Barnash K, Adam A, Ichikawa K, Huang L, Gu CH, Voigt J, Millan D, Chan HM, Decicco C, Hentemann M, Bellon SF, Wilson KJ.
Vaswani RG, et al. Among authors: chan hm.
J Med Chem. 2025 Jan 12. doi: 10.1021/acs.jmedchem.4c02535. Online ahead of print.
J Med Chem. 2025.
PMID: 39801091